C4X Discovery (C4XD), a drug development company with a leading technology for rational drug discovery and design has successfully floated on the AIM market of the London Stock Exchange with approximately £31M placed. The technology which underpins C4XD’s service was made possible in part due to sustained funding from BBSRC.
The Genome Analysis Centre (TGAC) will lead research into the development of bioinformatics to support the identification and characterisation of viruses through metagenomics. The BBSRC-funded research, led by TGAC’s Dr Richard Leggett, aims to develop computational algorithms that can accurately assemble viral genomes contained within metagenomic samples.
A major breakthrough by scientists at the University of Dundee in the study of a set of human proteins has the potential to unlock a huge new area of drug discovery for many diseases including cancer and inflammatory conditions. The research team led by Dr Alessio Ciulli in the College of Life Sciences at Dundee have developed a new method of selectively targeting the proteins known as BET bromodomains using small molecules.